---
title: "002923.SZ (002923.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002923.SZ/news.md"
symbol: "002923.SZ"
name: "002923.SZ"
parent: "https://longbridge.com/en/quote/002923.SZ.md"
datetime: "2026-05-20T09:11:49.006Z"
locales:
  - [en](https://longbridge.com/en/quote/002923.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002923.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002923.SZ/news.md)
---

# 002923.SZ (002923.SZ) — Related News

### [Rundu Pharma: Received approval for the listing application of the chemical raw material drug Telmisartan](https://longbridge.com/en/news/286756655.md)
*2026-05-18T10:41:02.000Z*
> Recently, Rundu Pharma received approval from the National Medical Products Administration for the market launch of the 

### [One of the actual controllers of Rundu Pharma, Li Xi, plans to reduce his holdings by no more than 3%](https://longbridge.com/en/news/285390239.md)
*2026-05-06T13:45:06.000Z*
> Rundu Pharma announced that its controlling shareholder and actual controller Li Xi plans to reduce his holdings by no m

### [Rundu Pharma: Received the approval notice for the listing application of the chemical raw material drug Losartan Potassium](https://longbridge.com/en/news/285181286.md)
*2026-05-05T09:48:19.000Z*
> Rundu Pharma announced that the company recently received the "Approval Notice for the Market Application of Chemical Ra

### [Rundu Pharma reports its first loss since going public: a net loss of 63.47 million yuan in 2025, with its subsidiary losing 117 million yuan. Can the newly approved global first-class innovative drug and the cross-border food sector save the situation?](https://longbridge.com/en/news/284304241.md)
*2026-04-28T03:13:17.000Z*
> Rundu Pharma (SZ002923) disclosed in its 2025 annual report that its annual operating revenue was 1.176 billion yuan, a 

### ["A-Share Focus" Pharmaceutical leader reports good performance, drug stocks boosted, Asymchem hits the upper limit](https://longbridge.com/en/news/284295925.md)
*2026-04-28T02:04:00.000Z*
> Pharmaceutical leader WuXi AppTec released its first-quarter report, with revenue of 12.436 billion yuan, a year-on-year

### [Rundu Pharma: Net profit in the first quarter was 15.6038 million yuan, a year-on-year increase of 735.25%](https://longbridge.com/en/news/284227808.md)
*2026-04-27T13:38:02.000Z*
> Rundu Pharma announced that its revenue for the first quarter of 2026 was 349 million yuan, a year-on-year increase of 3

### [Rundu Pharma: Approved for the listing application of hydrochloride dextromethorphan chemical raw materials](https://longbridge.com/en/news/283457321.md)
*2026-04-21T07:48:25.000Z*
> Rundu Pharma recently received approval from the National Medical Products Administration for the listing application of